← Human Trials & Peer-Reviewed Studies
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial
Plain-language guide to PMID 30422235 (2018): single-blind randomized controlled trial study of Somatostatin and Lanreotide in 309 patients.
Key Facts
- PMID
- 30422235
- Journal
- JAMA
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Meijer E et al. (23 authors)
- DOI
- 10.1001/jama.2018.15870
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin and Lanreotide.
To examine the effect of the somatostatin analogue lanreotide on the rate of kidney function loss in patients with later-stage ADPKD.
Why It Was Studied
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy.
There are limited therapeutic management options.
Who Took Part
The abstract describes 309 patients taking part.
The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.
An open-label randomized clinical trial with blinded end point assessment that included 309 patients with ADPKD from July 2012 to March 2015 at 4 nephrology outpatient clinics in the Netherlands.
How the Study Was Run
The researchers set it up as a randomized, single-blind and open-label study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
In this single-blind Somatostatin study one party knew the assignments and the other did not.
Being open-label, the Somatostatin study did not mask who received what.
Follow-up of the 2.5-year trial ended in August 2017.
What Was Measured
PubMed files the paper under topics including Glomerular Filtration Rate, Kidney, Peptides, Cyclic, Polycystic Kidney, Autosomal Dominant, Quality of Life, Renal Dialysis and Somatostatin.
What This Means in Plain Language
The paper is a randomized, single-blind and open-label study of Somatostatin and Lanreotide in 309 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (JAMA), a journal based in United States.
More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.